Pfizer Financial Statements

Pfizer (PFIZER) reported revenue of ₹24.54B in FY2025 with net income of ₹7.68B. Total assets stood at ₹49.11B and free cash flow was ₹6.32B.

Pfizer Income Statement

Hover the chart icon for year-over-year change.

FY 2021 – FY 2025

Item	Chart	2021	2022	2023	2024	2025
Revenue		23.20B	26.74B	25.26B	23.74B	24.54B
Cost of Rev. Cost of Revenue		-7.98B	-9.48B	-8.74B	-7.93B	-8.10B
Gross Profit		15.22B	17.26B	16.52B	15.81B	16.43B
SGA Sales, General & Admin		-7.29B	-8.27B	-7.42B	-7.65B	-7.31B
Op. Income Operating Income		6.84B	7.83B	8.04B	7.54B	8.52B
PBT Profit Before Tax		6.69B	7.73B	8.24B	7.46B	10.16B
Net Income		4.98B	6.13B	6.24B	5.51B	7.68B
Dil. Shares Diluted Shares		45.75M	45.75M	45.75M	45.75M	45.75M
Diluted EPS		108.77	133.89	136.38	120.51	167.79

Figures in ₹ — millions (M), billions (B), trillions (T). EPS is earnings per share.

Understanding the Income Statement

The income statement shows Pfizer's revenue and expenses over a period. Revenue minus costs gives gross profit; after operating expenses, interest, and taxes, the remainder is net income. Diluted EPS divides net income by all shares that could exist if options and convertibles were exercised.

Pfizer Balance Sheet

Hover the chart icon for year-over-year change.

FY 2021 – FY 2025

Item	Chart	2021	2022	2023	2024	2025
Curr. assets Total current assets		19.25B	23.96B	25.25B	27.38B	35.13B
Non-curr. assets Total non-current assets		13.41B	15.04B	14.76B	14.91B	13.98B
Total assets		32.66B	39.01B	40.01B	42.29B	49.11B
Curr. liabilities Total current liabilities		7.74B	8.53B	6.57B	5.47B	5.70B
Non-curr. liab. Total non-current liabilities		985.20M	1.83B	1.36B	866.80M	1.24B
Total liabilities		8.73B	10.36B	7.93B	6.33B	6.94B
Total equity		23.93B	28.64B	32.07B	35.96B	42.17B
Total liab. & eq. Total liabilities & equity		32.66B	39.01B	40.01B	42.29B	49.11B

Figures in ₹ — millions (M), billions (B), trillions (T).

Understanding the Balance Sheet

The balance sheet captures Pfizer's financial position at a point in time — what it owns (assets), what it owes (liabilities), and the residual value to shareholders (equity). Total assets always equals total liabilities plus equity.

Pfizer Cash Flow Statement

Hover the chart icon for year-over-year change.

FY 2021 – FY 2025

Item	Chart	2021	2022	2023	2024	2025
Net Income		6.69B	7.73B	8.24B	7.46B	10.16B
Operating CF Cash flow Operating Activities		4.27B	6.67B	3.56B	2.57B	6.60B
Capex Investments in PPE		-177.00M	-153.10M	-649.80M	-189.30M	-281.50M
Investing CF Cash flow Investing Activities		-4.69B	-5.75B	-360.50M	537.00M	-713.40M
Dividend Paid		-15.19B	-1.60B	-2.97B	-1.83B	-1.60B
Financing CF Cash flow Financing Activities		-15.71B	-1.81B	-3.46B	-2.35B	-2.05B
Cash (start) Cash at beginning of period		17.64B	1.51B	627.60M	366.00M	1.12B
Cash (end) Cash at end of period		1.51B	627.60M	366.00M	1.12B	4.95B
FCF Free Cash Flow		4.10B	6.52B	2.91B	2.38B	6.32B

Figures in ₹ — millions (M), billions (B), trillions (T).

Understanding Cash Flow

The cash flow statement tracks how Pfizer's cash moves through operations, investing, and financing activities. Free cash flow — operating cash minus capital expenditure — shows what is available to return to shareholders.

Data from audited consolidated filings. For educational purposes only — not investment advice. Last update: Mar-2025